<?xml version='1.0' encoding='utf-8'?>
<document id="23845193"><sentence text="Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma."><entity charOffset="56-69" id="DDI-PubMed.23845193.s1.e0" text="glibenclamide" /><entity charOffset="74-83" id="DDI-PubMed.23845193.s1.e1" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.23845193.s1.e0" e2="DDI-PubMed.23845193.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23845193.s1.e0" e2="DDI-PubMed.23845193.s1.e1" /></sentence><sentence text="There is increasing evidence that tyrosine kinase inhibitors (TKIs) have significant blood glucose lowering effects"><entity charOffset="34-42" id="DDI-PubMed.23845193.s2.e0" text="tyrosine" /><entity charOffset="91-98" id="DDI-PubMed.23845193.s2.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23845193.s2.e0" e2="DDI-PubMed.23845193.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23845193.s2.e0" e2="DDI-PubMed.23845193.s2.e1" /></sentence><sentence text=" A 70-year old Caucasian male with liver cirrhosis Child-Pugh A, advanced hepatocellular carcinoma and diabetes had a stable glycemic control being treated with glibenclamide (3"><entity charOffset="161-174" id="DDI-PubMed.23845193.s3.e0" text="glibenclamide" /></sentence><sentence text="5 mg twice daily)" /><sentence text=" After the first daily dose of the TKI sorafenib (800 mg) the patient experienced acute nocturnal disorientation and somnolence with a corresponding blood glucose of 37 mg/dl"><entity charOffset="39-48" id="DDI-PubMed.23845193.s5.e0" text="sorafenib" /><entity charOffset="155-162" id="DDI-PubMed.23845193.s5.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23845193.s5.e0" e2="DDI-PubMed.23845193.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23845193.s5.e0" e2="DDI-PubMed.23845193.s5.e1" /></sentence><sentence text=" After administration of glucose intravenously the neurological disturbances were completely reversible"><entity charOffset="25-32" id="DDI-PubMed.23845193.s6.e0" text="glucose" /></sentence><sentence text=" As there was no intercurrent deterioration neither of hepatic nor of renal function, the severe hypoglycemia can likely be attributed to a drug-drug interaction of sorafenib with the sulfonylurea"><entity charOffset="165-174" id="DDI-PubMed.23845193.s7.e0" text="sorafenib" /><entity charOffset="184-196" id="DDI-PubMed.23845193.s7.e1" text="sulfonylurea" /><pair ddi="false" e1="DDI-PubMed.23845193.s7.e0" e2="DDI-PubMed.23845193.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23845193.s7.e0" e2="DDI-PubMed.23845193.s7.e1" /></sentence><sentence text=" The complete inhibition of the CYP2C9 and CYP3A4 mediated metabolic pathway of glibenclamide through sorafenib might have resulted in a rapid accumulation of glibenclamide"><entity charOffset="80-93" id="DDI-PubMed.23845193.s8.e0" text="glibenclamide" /><entity charOffset="102-111" id="DDI-PubMed.23845193.s8.e1" text="sorafenib" /><entity charOffset="159-172" id="DDI-PubMed.23845193.s8.e2" text="glibenclamide" /><pair ddi="false" e1="DDI-PubMed.23845193.s8.e0" e2="DDI-PubMed.23845193.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23845193.s8.e0" e2="DDI-PubMed.23845193.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23845193.s8.e0" e2="DDI-PubMed.23845193.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23845193.s8.e1" e2="DDI-PubMed.23845193.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23845193.s8.e1" e2="DDI-PubMed.23845193.s8.e2" /></sentence><sentence text=" Profound blood glucose lowering effects of sorafenib might have additionally contributed to the hypoglycemic episode"><entity charOffset="16-23" id="DDI-PubMed.23845193.s9.e0" text="glucose" /><entity charOffset="44-53" id="DDI-PubMed.23845193.s9.e1" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.23845193.s9.e0" e2="DDI-PubMed.23845193.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23845193.s9.e0" e2="DDI-PubMed.23845193.s9.e1" /></sentence><sentence text=" " /></document>